The agency’s reasoning included the patient population for the trial, which the FDA said was low-risk and may not have truly needed an autograft or the Augment Bone Graft. In order to receive approval in the future, Wright Medical will need to prove patients in the trial are high-risk, according to the report.
More Articles on Devices:
Medtronic Acquires Cardiocom Disease Management Company for $200M
RTI Surgical’s Biologic Bone Graft Implanted in First Human Subject
SBi Launches Charcot Foot Solutions Website
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
